Skip to main content
Premium Trial:

Request an Annual Quote

Aventis Licenses Genomica s Discovery Manager Software

NEW YORK, Nov 2 - Genomica said Thursday it had licensed its Discovery Manager software to Aventis Pharma for an undisclosed sum of money.

" Discovery Manager is a powerful genomics software product that provides bench scientists with many features including the ability to rapidly perform large numbers of gene sequence analyses through a customizable sequence analysis algorithm pipeline," Paul August, senior associate scientist in Aventis’ molecular genomics department, said in a statement.

" We expect that the automation features of Discovery Manager will expedite functional genomics projects at the Aventis Cambridge genomics c enter," he said.

Discovery Manager is designed to allow researchers to be able to access, integrate, manipulate, analyze, and annotate data from a variety of sources. The package also includes a database template that allows researchers to combine their data with information retrieved from other databases.

Aventis Pharma said it would use the software to an analyze ESTs and to convert them into the corresponding cDNA. The company said that it did an “extensive search” to find commercially available software. It did not disclose the names of the other products it evaluated.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.